Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Ovid Therapeutics Inc. (OVID)
|
Add to portfolio |
|
|
|
| Price: |
$3.66
| | Metrics |
| OS: |
70.6
|
M
| |
-44
|
% ROE
|
| Market cap: |
$258
|
M
| |
-93
|
% ROIC
|
|
Net cash:
|
$113
|
M
| |
$1.60
|
per share
|
|
EV:
|
$145
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($53.4)
|
M
| |
|
|
|
EBIT
|
($54.0)
|
M
| |
|
|
| EPS |
($0.70)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-05-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 1.5 | 208.4 | 208.4 | 12.6 | 12.6 | 62.4 | 0.0 | 0.0 |
| Revenue growth | -99.3% | 1551.6% | 1551.6% | -79.8% | | | | |
| Cost of goods sold | 0.0 | 0.0 | 84.2 | 0.0 | 94.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 1.5 | 208.4 | 124.2 | 12.6 | -81.4 | 62.4 | 0.0 | 0.0 |
| Gross margin | 100.0% | 100.0% | 59.6% | 100.0% | -645.4% | 100.0% | | |
| Selling, general and administrative | | | | 94.0 | | | | |
| Research and development | 24.6 | 46.9 | | | | 42.2 | 33.8 | 50.0 |
| General and administrative | 32.4 | 37.2 | 37.2 | | 30.6 | 19.3 | 19.1 | 15.0 |
| EBITA | -55.4 | 124.4 | 124.2 | -81.2 | -81.4 | -61.2 | -52.8 | -65.0 |
| EBITA margin | -3683.6% | 59.7% | 59.6% | -643.4% | -645.4% | -98.1% | | |
| Amortization of intangibles | 0.2 | 0.2 | | 0.2 | | 0.2 | 0.1 | 0.1 |
| EBIT | -55.5 | 124.2 | 124.2 | -81.4 | -81.4 | -61.4 | -52.9 | -65.0 |
| EBIT margin | -3696.4% | 59.6% | 59.6% | -645.4% | -645.4% | -98.5% | | |
| Pre-tax income | -54.2 | 124.2 | 124.2 | -81.0 | -81.0 | -60.5 | -52.0 | -64.8 |
| Income taxes | 0.0 | 1.3 | 1.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 1.1% | 1.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -54.2 | 122.8 | 122.8 | -81.0 | -81.0 | -60.5 | -52.0 | -64.8 |
| Net margin | -3604.7% | 58.9% | 58.9% | -642.3% | -642.3% | -97.0% | | |
| |
| Diluted EPS | ($0.77) | $1.80 | $1.80 | ($1.39) | ($1.39) | ($1.54) | ($2.11) | ($3.35) |
| Shares outstanding (diluted) | 70.4 | 68.1 | 68.1 | 58.5 | 58.5 | 39.2 | 24.6 | 19.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|